CN1228701A - 具有溶解血栓活性的杂环化合物及其治疗血栓形成的用途 - Google Patents

具有溶解血栓活性的杂环化合物及其治疗血栓形成的用途 Download PDF

Info

Publication number
CN1228701A
CN1228701A CN97197579A CN97197579A CN1228701A CN 1228701 A CN1228701 A CN 1228701A CN 97197579 A CN97197579 A CN 97197579A CN 97197579 A CN97197579 A CN 97197579A CN 1228701 A CN1228701 A CN 1228701A
Authority
CN
China
Prior art keywords
group
ketone
pyrimidines
benzyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97197579A
Other languages
English (en)
Chinese (zh)
Inventor
J-P·杜宾
R·格莱戈里弗斯基
D·格拉维尔
F·卡萨德拜格
G·侯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1228701A publication Critical patent/CN1228701A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN97197579A 1996-07-12 1997-07-11 具有溶解血栓活性的杂环化合物及其治疗血栓形成的用途 Pending CN1228701A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR96/08969 1996-07-12
FR9608969A FR2750862B1 (fr) 1996-07-12 1996-07-12 Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques

Publications (1)

Publication Number Publication Date
CN1228701A true CN1228701A (zh) 1999-09-15

Family

ID=9494163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97197579A Pending CN1228701A (zh) 1996-07-12 1997-07-11 具有溶解血栓活性的杂环化合物及其治疗血栓形成的用途

Country Status (7)

Country Link
EP (1) EP0912180A1 (ja)
JP (1) JP2000514447A (ja)
CN (1) CN1228701A (ja)
AU (1) AU3696897A (ja)
CA (1) CA2260965A1 (ja)
FR (1) FR2750862B1 (ja)
WO (1) WO1998002162A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100486982C (zh) * 2001-11-02 2009-05-13 中国人民解放军军事医学科学院毒物药物研究所 具有预防和治疗血栓性疾病功能的化合物,含它们的药物组合物和它们的医药用途
CN100500679C (zh) * 2001-11-01 2009-06-17 中国人民解放军军事医学科学院毒物药物研究所 具有调节血管内皮细胞功能活性的化合物及其制备方法和用途

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
US6469014B1 (en) 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
ATE280171T1 (de) * 1998-12-23 2004-11-15 Bristol Myers Squibb Pharma Co Stickstoffhaltige heterobicyclen als faktor-xa- hemmer
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
EP1377576A2 (en) 2001-03-26 2004-01-07 Novartis AG Pyridine derivatives
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
TW200951139A (en) 2008-05-27 2009-12-16 Astrazeneca Ab Chemical compounds 293
US20120122889A1 (en) * 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
EP3253759A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3094988A1 (en) 2018-03-30 2019-10-03 Biotheryx, Inc. Thienopyrimidinone compounds
JPWO2021054393A1 (ja) * 2019-09-19 2021-03-25

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02169520A (ja) * 1988-12-22 1990-06-29 Tsumura & Co 微小循環改善剤
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100500679C (zh) * 2001-11-01 2009-06-17 中国人民解放军军事医学科学院毒物药物研究所 具有调节血管内皮细胞功能活性的化合物及其制备方法和用途
CN100486982C (zh) * 2001-11-02 2009-05-13 中国人民解放军军事医学科学院毒物药物研究所 具有预防和治疗血栓性疾病功能的化合物,含它们的药物组合物和它们的医药用途

Also Published As

Publication number Publication date
JP2000514447A (ja) 2000-10-31
FR2750862B1 (fr) 1998-10-16
CA2260965A1 (en) 1998-01-22
FR2750862A1 (fr) 1998-01-16
EP0912180A1 (fr) 1999-05-06
AU3696897A (en) 1998-02-09
WO1998002162A1 (fr) 1998-01-22

Similar Documents

Publication Publication Date Title
CN1228701A (zh) 具有溶解血栓活性的杂环化合物及其治疗血栓形成的用途
JP6700311B2 (ja) キナーゼ阻害剤である複素環式アミド
KR102564925B1 (ko) 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
CN1131854C (zh) 作为速激肽受体拮抗剂的1－(1,2－二取代哌啶基)－4－取代哌啶衍生物
JP6318156B2 (ja) キナーゼをモジュレートするための化合物および方法、ならびにその指標
ZA200501227B (en) Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists
CN1304365C (zh) 酰化的芳基环烷基胺和它们作为药物的用途
DK2592081T3 (en) TETRAHYDROCARBOLIN DERIVATIVES
WO2015107724A1 (ja) 縮合５－オキサゾリジノン誘導体
CN1208415A (zh) 抑制血管生成的哒嗪胺
JP6836996B2 (ja) 新しいトリフルオロメチルプロパンアミド誘導体
CN1165482A (zh) 用作蛋白激酶抑制剂的吡唑药物组合物
KR20070097590A (ko) 치환된 아릴아민 화합물 및 5―ｈｔ6 조절제로서의 이의용도
CN102596200A (zh) 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类
JP2002539126A (ja) チロシンキナーゼ阻害剤
NO315373B1 (no) Spirosykliske metallprotease-inhibitorer
TW201619133A (zh) 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
CN109963561A (zh) 可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲哚衍生物
CN1780663A (zh) 作为肾素抑制剂的新型3－位具有杂原子的9－氮杂双环壬烯衍生物
TW201026665A (en) Indolinone compounds as kinase inhibitors
CN1585750A (zh) 邻氨基苯甲酰胺和其作为vegf受体酪氨酸激酶抑制剂的用途
CN105384739A (zh) 吡唑并[3,4-c]吡啶类衍生物
CN1149996C (zh) 抗精神病药哌啶并[4,3-b]吲哚衍生物
CN1780833A (zh) 托品烷衍生物及其作为血管紧张肽转化酶抑制剂的应用
US7405210B2 (en) Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication